Rationale and Design of the “Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial:” A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combined Diuretic Therapy (Loop Diuretics With Thiazide-Type Diuretics) Among Patients With Decompensated Heart Failure

Journal of Cardiac Failure

Volumn 22, Issue 7, 2016, Pages 529-536

  Trullàs, Joan Carles ^a,b   Morales Rull, José Luís ^c   Casado, Jesús ^d   Freitas Ramírez, Adriana ^e   Manzano, Luís ^f   Formiga, Francesc ^g  

^a Hospital d'Olot   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^e GENERALITAT DE CATALUNYA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

diuretics; furosemide; Heart failure; hydrochlorothiazide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BENDROFLUMETHIAZIDE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METOLAZONE; NATRIURETIC FACTOR; PLACEBO; PROTEIN; DIURETIC AGENT;

ACUTE HEART FAILURE; ADD ON THERAPY; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHLORIDE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY FAILURE; LIPID ANALYSIS; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINALYSIS; WEIGHT REDUCTION; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG TOLERANCE; HEART FAILURE; METHODOLOGY; TREATMENT OUTCOME;

CHRONIC DISEASE; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FUROSEMIDE; HEART FAILURE; HUMANS; HYDROCHLOROTHIAZIDE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84951140765     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.11.003     Document Type: Article

References (40)

1. 1 Roger, V.L., Epidemiology of heart failure. Circ Res 113 (2013), 646–659.
2. 2 von Lueder, T.G., Atar, D., Krum, H., Diuretic use in heart failure and outcomes. Clin Pharmacol Ther 94 (2013), 490–498.
3. 3 ter Maaten, J.M., Valente, M.A., Damman, K., Hillege, H.L., Navis, G., Voors, A.A., Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol 12 (2015), 184–192.
4. 4 Felker, G.M., O'Connor, C.M., Braunwald, E., Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circ Heart Fail 2 (2009), 56–62.
5. 5 Felker, G.M., Lee, K.L., Bull, D.A., Redfield, M.M., Stevenson, L.W., Goldsmith, S.R., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364 (2011), 797–805.
6. 6 Leto, L., Aspromonte, N., Feola, M., Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 19 (2014), 237–246.
7. 7 Wu, M.Y., Chang, N.C., Su, C.L., Hsu, Y.H., Chen, T.W., Lin, Y.F., et al. Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials. J Crit Care 29 (2014), 2–9.
8. 8 Neuberg, G.W., Miller, A.B., O'Connor, C.M., Belkin, R.N., Carson, P.E., Cropp, A.B., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002), 31–38.
9. 9 Ellison, D.H., Diuretic therapy and resistance in congestive heart failure. Cardiology 96 (2001), 132–143.
10. 10 Kim, G.H., Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 24 (2004), 595–605.
11. 11 Loon, N.R., Wilcox, C.S., Unwin, R.J., Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 36 (1989), 682–689.
12. 12 Costanzo, M.R., Saltzberg, M.T., Jessup, M., Teerlink, J.R., Sobotka, P.A., Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail 16 (2010), 277–284.
13. 13 Bart, B.A., Goldsmith, S.R., Lee, K.L., Givertz, M.M., O'Connor, C.M., Bull, D.A., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 6 (2012), 1–9.
14. 14 Chen, H.H., Anstrom, K.J., Givertz, M.M., Stevenson, L.W., Semigran, M.J., Goldsmith, S.R., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310 (2013), 2533–2543.
15. 15 Gheorghiade, M., Konstam, M.A., Burnett, J.C. Jr, Grinfeld, L., Maggioni, A.P., Swedberg, K., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. JAMA 297 (2007), 1332–1343.
16. 16 O'Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
17. 17 Paterna, S., Fasullo, S., Parrinello, G., Cannizzaro, S., Basile, I., Vitrano, G., et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association Class III (Class C) (SMAC-HF Study). Am J Med Sci 342 (2011), 27–37.
18. 18 Ellison, D.H., The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 114 (1991), 886–894.
19. 19 Reubi, F., Cottier, P., Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 23 (1961), 200–210.
20. 20 Brater, D.C., Diuretic therapy. N Engl J Med 339 (1998), 387–389.
21. 21 Dussol, B., Moussi-Frances, J., Morange, S., Somma-Delpero, C., Mundler, O., Berland, Y., A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens 14 (2012), 32–37.
22. 22 Jentzer, J.C., DeWald, T.A., Hernandez, A.F., Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56 (2010), 1527–1534.
23. 23 Sigurd, B., Olesen, K.H., Wennevold, A., The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide. Am Heart J 89 (1975), 163–170.
24. 24 Dormans, T.P.J., Gerlag, P.G., Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 17 (1996), 1867–1874.
25. 25 Aravot, D.J., Banner, N.R., Musumeci, F., Fitzgerald, M., Khaghani, A., Radley-Smith, R., et al. Oral metolazone plus frusemide for home therapy in patients with refractory heart failure. Lancet 333 (1989), 727–728.
26. 26 Kiyingi, A., Field, M.J., Pawsey, C.C., Yiannikas, J., Lawrence, J.R., Arter, W.J., Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 335 (1990), 29–31.
27. 27 Mouallem, M., Brif, I., Mayan, H., Farfel, Z., Prolonged therapy by the combination of furosemide and thiazides in refractory heart failure and other fluid retaining conditions. Int J Cardiol 50 (1995), 89–94.
28. 28 Channer, K.S., McLean, K.A., Lawson-Matthews, P., Richardson, M., Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 71 (1994), 146–150.
29. 29 Trullàs, J.C., Morales-Rull, J.L., Formiga, F., en representación del Grupo de Trabajo de Insuficiencia Cardiaca y Fibrilación Auricular de la Sociedad Española de Medicina Interna. Diuretic therapy in heart failure. Med Clin (Barc) 142 (2014), 163–7030.
30. 30 Fliser, D., Schröter, M., Neubeck, M., Ritz, E., Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 46 (1994), 482–488.
31. 31 Moranville, M.P., Choi, S., Hogg, J., Anderson, A.S., Rich, J.D., Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance. Cardiovasc Ther 33 (2015), 42–49.
32. 32 Trullàs, J.C., Morales-Rull, J.L., Formiga, F., Diuretic therapy in acute heart failure. Med Clin (Barc) 142:Suppl 1 (2014), 36–41.
33. 33 van Blijderveen, J.C., Straus, S.M., Rodenburg, E.M., Zietse, R., Stricker, B.H., Sturkenboom, M.C., et al. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med 127 (2014), 763–771.
34. 34 Dhalla, I.A., Gomes, T., Yao, Z., Nagge, J., Persaud, N., Hellings, C., et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med 158 (2013), 447–455.
35. 35 Valente, M.A., Voors, A.A., Damman, K., Van Veldhuisen, D.J., Massie, B.M., O'Connor, C.M., et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35 (2014), 1284–1293.
36. 36 Testani, J.M., Brisco, M.A., Turner, J.M., Spatz, E.S., Bellumkonda, L., Parikh, C.R., et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 7 (2014), 261–270.
37. 37 Bart, B.A., Goldsmith, S.R., Lee, K.L., Givertz, M.M., O'Connor, C.M., Bull, D.A., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 (2012), 2296–2304.
38. 38 Metra, M., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61 (2013), 196–206.
39. 39 Ander, D.S., Aisiku, I.P., Ratcliff, J.J., Todd, K.H., Gotsch, K., Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful?. Congest Heart Fail 10 (2004), 188–191.
40. 40 Teerlink, J.R., McMurray, J.J., Bourge, R.C., Cleland, J.G., Cotter, G., Jondeau, G., et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 150 (2005), 46–53.